Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Adlai Nortye Group Ltd. - American Depositary Shares
(NQ:
ANL
)
11.41
-0.68 (-5.62%)
Delayed Quote
Updated: 11:40 AM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Adlai Nortye Group Ltd. - American Depositary Shares
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
October 15, 2026
From
Adlai Nortye Group Ltd.
Via
GlobeNewswire
Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
September 30, 2026
From
Adlai Nortye Group Ltd.
Via
GlobeNewswire
Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC
September 08, 2026
From
Adlai Nortye Group Ltd.
Via
GlobeNewswire
Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress
August 14, 2026
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
August 03, 2026
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
July 16, 2026
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
July 13, 2026
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
April 16, 2026
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations
February 12, 2026
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Adlai Nortye Announces $140.0 Million Private Placement Equity Financing
February 03, 2026
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China
December 29, 2025
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Adlai Nortye to Participate in Upcoming Investor Conferences
November 21, 2025
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 22, 2025
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 13, 2025
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025
April 10, 2025
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress
August 08, 2024
Company Announces Appointment of Roger Sawhney, M.D. as a New Member of the Board of Directors
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors
August 08, 2024
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
May 23, 2024
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
May 22, 2024
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
March 29, 2024
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC
November 17, 2023
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award
October 23, 2023
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Adlai Nortye Ltd. Announces Closing of Initial Public Offering
October 03, 2023
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
